What is the recommended evaluation and management for left axillary lymphadenopathy?

Evaluation and Management of Left Axillary Lymphadenopathy

Begin with combined axillary ultrasound and diagnostic mammography (or digital breast tomosynthesis) of the ipsilateral breast to identify both nodal characteristics and any occult breast primary malignancy. 1

Initial Diagnostic Approach

First-Line Imaging

• Axillary ultrasound is the cornerstone initial test because it distinguishes solid from cystic lesions, evaluates cortical thickness, assesses hilum integrity, and characterizes vascularity on Doppler imaging. 2, 1
• Diagnostic mammography or digital breast tomosynthesis must be performed concurrently to detect an occult ipsilateral breast cancer, which is the primary concern in unilateral axillary lymphadenopathy. 2, 1
• In women without known breast cancer presenting with axillary lymphadenopathy, only approximately 7% harbor malignancy on biopsy, with prevalence increasing with age. 1

Critical History Elements

• Document COVID-19 vaccination status including date(s), laterality of injection (left vs. right arm), and vaccine type, as mRNA vaccines cause axillary lymphadenopathy in 0.3–53% of recipients with average duration exceeding 100 days. 3, 4
• Assess for systemic symptoms: fever, night sweats, unintentional weight loss (suggesting lymphoma or systemic disease). 5
• Elicit recent infections, autoimmune conditions, occupational exposures, travel history, animal contacts, and medication use. 5
• Inquire about personal or family history of breast cancer, melanoma, head/neck cancer, or lymphoma. 1

Sonographic Criteria for Biopsy vs. Observation

Proceed Directly to Ultrasound-Guided Core Biopsy When:

• Complete loss of the central fatty hilum 1
• Rounded (rather than oval) node shape 1
• Increased vascularity on Doppler imaging 1
• Cortical thickening with loss of cortical-hilum differentiation 6

Observation Is Appropriate When:

• Preserved fatty hilum with normal cortical thickness 1
• Benign-appearing lesions such as lipomas require no further evaluation. 2

Vaccine-Related Lymphadenopathy: Risk-Stratified Management

Low-Risk Patients (No Cancer History)

• If lymphadenopathy is ipsilateral to COVID-19 vaccination given ≤3 months prior and imaging shows no suspicious features, manage expectantly without routine follow-up imaging. 1
• If lymphadenopathy persists >3 months after vaccination, perform sonographic follow-up after an additional 3 months. 1, 3
• Biopsy is indicated if nodes are persistent, progressive, or develop suspicious morphology at follow-up. 3, 7

High-Risk Patients (Known or Suspected Malignancy)

• Proceed directly to tissue biopsy regardless of vaccination timing in patients with known breast cancer, melanoma, head/neck cancer, or lymphoma. 1, 8
• Do not delay cancer staging or treatment to await resolution of possible vaccine-related adenopathy; accept the risk of false-positive findings and perform minimally invasive biopsy. 3, 7
• For newly diagnosed breast cancer, standard preoperative staging should proceed without delay according to guidelines. 3, 8

Screening Mammography Timing

• Schedule screening mammography before vaccination or ≥4–6 weeks after the final vaccine dose to reduce false-positive findings. 1

Advanced Imaging: When and Why

Breast MRI

• Indicated when mammography is negative but axillary nodes remain suspicious on ultrasound, as MRI detects occult breast cancer in more than two-thirds of patients with unexplained axillary lymphadenopathy. 2, 1
• MRI also characterizes axillary mass involvement of adjacent vessels, chest wall, and other axillary structures. 2

CT Chest/Abdomen/Pelvis

• Not routinely indicated for asymptomatic early-stage breast cancer because the yield for occult disease is low. 2, 1
• Reserve CT for patients with elevated liver function tests, pulmonary or abdominal symptoms, or abnormal physical examination findings. 2
• CT can visualize axillary levels I, II, and III but has insufficient predictive accuracy to replace sentinel lymph node biopsy. 2

FDG-PET/CT

• Do not use as the initial imaging modality for isolated axillary lymphadenopathy of unknown cause; it provides no diagnostic benefit in this setting. 1
• Advanced imaging with PET/CT has low yield for occult disease in asymptomatic women with early-stage breast cancer. 2

Management in the Context of Breast Cancer

Clinically Node-Negative Early Breast Cancer (T1–T2, ≤2 cm)

• Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as the standard staging procedure, based on the Z0011 trial demonstrating non-inferior 10-year overall survival with markedly lower morbidity. 2, 9, 1
• Perform preoperative axillary ultrasound to identify patients with higher nodal disease burden who may benefit from upfront biopsy. 1
• When suspicious nodes are identified on ultrasound, perform ultrasound-guided core biopsy with marker-clip placement. 1

Limited Sentinel Node Metastasis (1–2 Positive Nodes)

• For patients with 1–2 sentinel lymph node micrometastases or macrometastases treated with breast conservation and systemic therapy, completion ALND is not recommended because it does not improve overall survival, disease-free survival, or recurrence rates compared to SLNB alone. 9, 1
• This recommendation applies to patients undergoing breast-conserving surgery with whole-breast radiation and systemic therapy. 9

Neoadjuvant Chemotherapy Setting

• Place a marker clip in the biopsy-proven positive node before neoadjuvant treatment. 1
• Targeted axillary dissection (removal of the clipped node plus sentinel nodes) is preferred over complete ALND, lowering the false-negative rate to 8.4–8.7% when ≥3 sentinel nodes—including the clipped node—are removed. 1

Bilateral Axillary Lymphadenopathy

• Differential diagnosis includes systemic diseases (lymphoma, leukemia, autoimmune disorders), bilateral breast cancer (rare), and infectious/inflammatory conditions. 2, 1
• Initial imaging: bilateral axillary ultrasound plus diagnostic mammography. 2, 1
• If mammography is negative but nodes remain suspicious, breast MRI is recommended to detect occult bilateral breast cancer. 1

Critical Pitfalls to Avoid

• Do not delay cancer staging or treatment in patients with known or suspected malignancy to await resolution of possible vaccine-related adenopathy. 1, 3
• Do not perform routine ALND in clinically node-negative or limited node-positive breast cancer; SLNB offers equivalent survival with reduced morbidity. 9, 1
• Do not use FDG-PET/CT as the initial imaging modality for an isolated axillary mass of unknown cause. 1
• Do not administer corticosteroids empirically, as they can mask the histologic diagnosis of lymphoma or other malignancy. 5
• Do not rely solely on ultrasound morphology to differentiate reactive from metastatic nodes in high-risk patients; histopathology evaluation is essential. 6